Modalis Therapeutics Corporation
Basic information
- Head office
- Tokyo, Japan
- Chief executive
- Haruhiko Morita
- Capital
- 100,000,000
- Employees (non-consolidated)
- 4 people
- Employees (consolidated)
- 50 people
- Start date
- 2018-04-01
- End date
Websites
Business
Related companies
| Company name | Group | Parent | Subsidiary | Customer | Supplier | Alliance | Bank | Shareholder |
|---|---|---|---|---|---|---|---|---|
|
|
Network
History
Founded EdiGENE Corporation (now Modalis Therapeutics Corporation)
Jan 2016 EdiGene Corporation founded
EdiGene Corporation founded
Established our subsidiary EdiGENE Inc. (now Modalis Therapeutics Inc.) in Cambridge, Massachusetts, USA
Apr 2016 Established fully owned US subsidiary, EdiGENE Inc. (Now Modalis Therapeutics Inc.)
Established fully owned US subsidiary, EdiGENE Inc. (Now Modalis Therapeutics Inc.)
Initial research collaboration formed with Astellas Pharma Inc.
Entered into an exclusive license agreement with the University of Tokyo regarding CRISPR technology
Sep 2017 Initial research collaboration formed with Astellas Pharma Inc.
Obtained license on engineered Cas9 technology from University of Tokyo
Feb 2019 Obtained license on engineered Cas9 technology from University of Tokyo
Established a license agreement on a genetic disorder with Astellas Pharma Inc.
The U.S. subsidiary relocated and expanded within Cambridge
Mar 2019 Established a license agreement on a genetic disorder with Astellas Pharma Inc.
US subsidiary relocated to the new facility
Changed company name to Modalis Therapeutics Corporation
Aug 2019 US subsidiary relocated to the new facility
EdiGene renamed to Modalis Therapeutics
Sep 2019 EdiGene renamed to Modalis Therapeutics
Established 2nd license agreement for additional genetic disorder with Astellas Pharma Inc.
Nov 2019 Established 2nd license agreement for additional genetic disorder with Astellas Pharma Inc.
Collaboration agreement with Eisai Co., Ltd.
Entered into a non-exclusive license agreement with Editas Medicine, Inc. for the implementation of CRISPR/Cas9 patents
Apr 2020 Collaboration agreement with Eisai Co., Ltd.
Modalis Obtains Access to Foundational CRISPR IP
Listed on the Tokyo Stock Exchange Mothers market (ticker: 4883)
Aug 2020 Modalis Obtains Access to Foundational CRISPR IP
Listing on Mothers, Tokyo Stock Exchange (Ticker symbol: 4883)
About Oct 2021 US subsidiary relocated to the new facility
The U.S. subsidiary relocated and expanded within Waltham
Oct 2021 Listing on Mothers, Tokyo Stock Exchange (Ticker symbol: 4883)
US subsidiary relocated to the new facility
News
There is no news.
Public records
National Tax Agency basic information1010001172984
- Trade name
- 株式会社モダリス
- Trade name (kana)
- モダリス
- Name in English
- Modalis Therapeutics Corporation
- Corporation type
- 301
- Address
- 〒103-0023 東京都中央区日本橋本町３丁目１１番５号
- Postal code
- 1030023
- Prefecture code
- 13
- City code
- 102
- Address outside Japan
- Prefecture in English
- Tokyo
- City in English
- 3-11-5 Nihonbashi-Honcho, Chuo ku
- Address outside Japan in English
- Corporate number assignment date
- 2016-01-20
- Update date
- 2025-05-26
- Change date
- 2020-09-14
- Registry closure date
- Reason for registry closure
- Successor corporate number
- Details of the change
- Latest record
- 1
- Excluded from search
- 0
- Processing type
- 12
- Correction type
- 1
- Trade name image ID
- Address image ID
- Sequence number
- 1279237
METI gBizINFO1010001172984
- Corporate number
- 1010001172984
- Trade name
- 株式会社モダリス
- Trade name (kana)
- モダリス
- Trade name (alphabet)
- Modalis Therapeutics Corporation
- Registry closure date
- Reason for registry closure
- Registered address
- 東京都中央区日本橋本町３丁目１１番５号
- Postal code
- 1030023
- Prefecture
- 東京都
- Prefecture code
- 13
- City or district
- 中央区
- City code
- 102
- Street address
- 日本橋本町３丁目１１番５号
- Organisation type
- 301
- Processing type
- 12
- Correction type
- 1
- Status
- Representative
- 代表取締役CEO 森田 晴彦
- Capital
- 1728097000
- Employees
- 3
- Employees (male)
- Employees (female)
- Business summary
- Website URL
- Year founded
- Business category
- Date established
- Unified government qualification - grade
- Unified government qualification - business items
- Update date
- 2025-05-26
- Key information
- 1010001172984